Aniling is a spin-off of the Institute of Predictive and Personalized Medicine of Cancer (IMPPC) focused on the improvement of Next Generation Sequencing methods to integrate molecular data into biologically meaning information fulfilling the high quality standards required in clinics. More info at aniling.com
The Institute of Predictive and Personalized Medicine of Cancer (IMPPC) aims to change the current model of diagnostic and curative medicine to a new model of preemptive and tailored medicine, focusing its activities on the field of cancer research. We are now closer than ever before to a new paradigm of personalized medicine, in which the genetic profile of healthy individuals will be stored with their medical history and used to predict disease before it develops. Indeed, this is already possible for some hereditary cancers and the work of the IMPPC aims to extend this to other forms of the disease as well as identifying new diagnostic and therapeutic tools.
Central tasks of the institute are to carry out basic and translational research that should ultimately have an impact in human health. At the same time, we aim to implement training and dissemination of new knowledge in genomic medicine to the medical professionals in particular, and society in general.